The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.
Virakul, Sita; Dalm, Virgil A S H; Paridaens, Dion; van den Bosch, Willem A; Hirankarn, Nattiya; van Hagen, P Martin; Dik, Willem A.
Graefes Arch Clin Exp Ophthalmol
; 252(7): 1101-9, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24874745
[Antifibrotic effect of pirfenidone on orbital fibroblasts in patients with thyroid-associated ophthalmopathy and its mechanisms].
Divergent Sp1 protein levels may underlie differential expression of UDP-glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Graves disease.
Pirfenidone attenuates the IL-1ß-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy.
Molecular biomarkers of Graves' ophthalmopathy.
Tocilizumab for thyroid eye disease.
Reversal of Pathological Features of Graves' Orbitopathy by Activation of Forkhead Transcription Factors, FOXOs.
Histamine induces NF-κB controlled cytokine secretion by orbital fibroblasts via histamine receptor type-1.
Deletion of Hyaluronan Synthase 3 Inhibits Neointimal Hyperplasia in Mice.
Elevated bone morphogenic protein 4 expression implicated in site-specific adipogenesis in thyroid associated orbitopathy.
Platelet-Derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts.